Clinical Trial Update: HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 [Phase 2, Phase 3]

View source ↗

Summary

The HEALEY ALS Platform Trial's Regimen F with ABBV-CLS-7262 completed Phase 2 and Phase 3 cohorts, with trial results posted on 2025-11-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ABBV-CLS-7262

Snippet

Sponsor: Merit E. Cudkowicz, MD | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-11-14